Long-term tocilizumab therapy in patients with corticosteroid-resistant active moderate-to-severe thyroid eye disease.

No abstract is available for this paper.

• Publication year

  2025

• Venue

  European Journal of Endocrinology

• Publication date

  2025-11-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/ejendo/lvaf227PMID 41208406
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Thyroid eye disease (Graves' orbitopathy): clinical presentation, epidemiology, pathogenesis, and management.

  2025cited by this paper
• A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patients

  2025cited by this paper
• The efficacy and safety of intravenous tocilizumab to treat Graves' ophthalmopathy: A systematic review and single-arm meta-analysis.

  2024cited by this paper
• Age and gender influence on clinical manifestations of thyroid-associated ophthalmopathy: a case series of 2479 Chinese patients

  2024cited by this paper
• Tocilizumab improves clinical outcome in patients with active corticosteroid-resistant moderate-to-severe Graves’ orbitopathy: an observational study

  2023cited by this paper
• Magnetic Resonance Imaging in the Management of Thyroid Eye Disease: A Systematic Review

  2023cited by this paper
• Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study

  2022cited by this paper
• Management of Thyroid Eye Disease: A Consensus Statement by the American Thyroid Association and the European Thyroid Association

  2022cited by this paper
• Treatment of corticosteroid-resistant Graves’ orbitopathy with tocilizumab: a single-centre prospective study

  2022cited by this paper
• Current concepts regarding Graves’ orbitopathy

  2022cited by this paper
• Steroid-Resistant Graves’ Orbitopathy Treated with Tocilizumab in Real-World Clinical Practice: A 9-Year Single-Center Experience

  2021cited by this paper
• Long‐term outcomes in corticosteroid‐refractory Graves' orbitopathy treated with tocilizumab

  2021cited by this paper
• A Modern Approach to Dyslipidemia

  2021cited by this paper
• THE 2021 EUROPEAN GROUP ON GRAVES' ORBITOPATHY (EUGOGO) CLINICAL PRACTICE GUIDELINES FOR THE MEDICAL MANAGEMENT OF GRAVES' ORBITOPATHY.

  2021cited by this paper
• Dixon-T2WI magnetic resonance imaging at 3 tesla outperforms conventional imaging for thyroid eye disease

  2021cited by this paper
• Teprotumumab for the Treatment of Active Thyroid Eye Disease.

  2020cited by this paper
• Tocilizumab versus Rituximab in Patients with Moderate to Severe Steroid-resistant Graves’ Orbitopathy

  2020cited by this paper
• Epidemiology, Natural History, Risk Factors, and Prevention of Graves’ Orbitopathy

  2020cited by this paper
• Anti-IL-6 Receptor Tocilizumab in Refractory Graves’ Orbitopathy: National Multicenter Observational Study of 48 Patients

  2020cited by this paper
• Anti-cyclic citrullinated peptide antibody titers decrease in rheumatoid arthritis patients treated with tocilizumab: A pilot study

  2019cited by this paper
• Immunological Aspects of Graves' Ophthalmopathy

  2019cited by this paper
• A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases

  2018cited by this paper
• Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial.

  2018cited by this paper
• Tocilizumab: A Review in Rheumatoid Arthritis

  2017cited by this paper
• Hyperthyroidism.

  2016cited by this paper
• Relationship between magnetic resonance imaging signal intensity and volume of extraocular muscles in thyroid-associated ophthalmopathy with methylprednisolone pulse therapy

  2016cited by this paper
• Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.

  2015cited by this paper
• Randomized controlled trial of rituximab in patients with Graves' orbitopathy.

  2015cited by this paper
• Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype

  2015cited by this paper
• The effect of B cell depletion therapy on anti‐TSH receptor antibodies and clinical outcome in glucocorticoid‐refractory Graves' orbitopathy

  2013cited by this paper
• CD8+CD28− Lymphocytes in Peripheral Blood and Serum Concentrations of Soluble Interleukin 6 Receptor are Increased in Patients with Graves’ Orbitopathy and Correlate with Disease Activity

  2012cited by this paper
• Correlation of signal intensity ratio on orbital MRI-TIRM and clinical activity score as a possible predictor of therapy response in Graves’ orbitopathy—a pilot study at 1.5 T

  2010cited by this paper
• Immune Mechanisms in Thyroid Eye Disease

  2008cited by this paper
• Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease.

  2006cited by this paper
• Signal intensity, clinical activity and cross-sectional areas on MRI scans in thyroid eye disease.

  2006cited by this paper
• Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy

  1997cited by this paper
• High circulating IL-6 level in Graves' ophthalmopathy.

  1997cited by this paper
• The initial clinical characteristics of Graves' orbitopathy vary with age and sex.

  1993cited by this paper
• Development and course of exophthalmos and ophthalmoplegia in Graves' disease with special reference to the effect of thyroidectomy.

  1945cited by this paper

• Macrophage plasticity in thyroid eye disease: dual effects of inflammation and fibrosis

  2026cites this paper